M. Alexander Shaw CEO

M. Alexander Shaw appointed CEO of Prolifagen Therapeutics. Learn more here

M2D2 200K Challenge

Prolifagen recently won an award at the M2D2 200K challenge. Learn more here

Deep Tech Pioneers
Among 5,000 applicants from 128 different countries, Prolifagen has been selected as one of @hello tomorrow’s Deep Tech Pioneers from their annual Global Challenge! Come and meet us at the virtual Hello Tomorrow Global Summit on 16th-20th November, 2020


Preventing the Development of Heart Failure

Our Background

Prolifagen is a preclinical spin-out of University of Pennsylvania developing a medicine for cardiac regeneration based on microRNA technology.  

Our Team

Our management team holds essential complementary skill sets in differing areas of domain expertise and bring decades of experience to this work.

Our Work

microRNA 302 drives proliferation of resident adult cardiac muscle cells in injured hearts, leading to reconstitution of functional heart muscle.